Skip to main navigation

Top Bar Nav

Contact Us

Social Icons

linkedin twitter

About Nav

About

Pioneering Pathways

Pioneering Pathways

Medicines Nav

Medicines

Science Nav

Science

Our Purpose Nav

Our Purpose

Our Stories

Our Stories

News Nav

News

IR Nav

Investors

Careers Nav

Careers

Home News Press Release Archive

Press Release Archive

News Nav

News
Press Release Archive
Events Archive
Our Stories

Media Contact

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc

Send Email
Ireland: +353 1 637 2141
US: 215-867-4948

Press Release Archive

Year

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

August 3, 2026

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

July 20, 2026

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

June 17, 2026

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

June 16, 2026

Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer

June 12, 2026

Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia

June 4, 2026

Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

May 27, 2026

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

May 5, 2026

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

April 27, 2026

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 614

About Nav

About

Pioneering Pathways Nav

Pioneering Pathways

Medicines Nav

Medicines

Science Nav

Science

Our Purpose Nav

Our Purpose

Our Stories Nav

Our Stories

News Nav

News

Careers Nav

Careers

IR Nav

Investors

© 2026 Jazz Pharmaceuticals plc All Rights Reserved.

Legal Nav

Privacy Statement
U.S. Consumer Health Data Privacy Policy
Terms of Use
Social Media Global Guidelines
Your Privacy Choices
Sitemap